Clinical Trial Update: SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating SHR-1210 in combination with Anlotinib for advanced or metastatic esophageal squamous cell cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: SHR-1210, Anlotinib | Phase 2 | Status: UNKNOWN